DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
52 hedge funds and large institutions have $14.6M invested in DMK Pharmaceuticals Corporation Common Stock in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 5 closing their positions.
255% more call options, than puts
Call options by funds: $2.53M | Put options by funds: $713K
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 51 → 52 (+1)
18% less capital invested
Capital invested by funds: $17.8M → $14.6M (-$3.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$566K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$513K |
| 3 |
VF
Virtu Financial
New York
|
+$214K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$204K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$71.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.78M |
| 2 |
GC
Greenlight Capital
New York
|
-$740K |
| 3 |
Goldman Sachs
New York
|
-$266K |
| 4 |
Squarepoint
New York
|
-$106K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$72.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Balyasny Asset Management
Chicago,
Illinois
| – | -$1.78M | -23,179 | Closed |
|
|
52
Goldman Sachs
New York
| – | -$266K | -3,457 | Closed |
|
|
HR
53
Hayden Royal
Charlotte,
North Carolina
| – | -$44K | -572 | Closed |
|
|
N
54
Natixis
Paris,
France
| – | -$42K | -551 | Closed |
|
55
Bessemer Group
Woodbridge,
New Jersey
| – | -$1K | -14 | Closed |
|
DMK Hedge Fund Activity: Q3 2021 in Review
52 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2021, worth a combined $14.6M — down 18% from $17.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMK positions and 5 closed out — a net gain of 1 holder — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, adding an estimated $566K. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.78M sold.
- 52 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2021, up from 51 in Q2 2021.
- Funds reported $14.6M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2021, down 18% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2021 and 5 closed out, a net change of +1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2021 was Millennium Management, an estimated $566K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2021 was Balyasny Asset Management, an estimated $1.78M sold.
Based on aggregated 13F filings for Q3 2021.